American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Here’s why the Bayer share price may rebound after earnings

by admin August 5, 2025
August 5, 2025
Here’s why the Bayer share price may rebound after earnings

Bayer share price pulled back to €27.6 on Tuesday as investors waited for its financial results. It has dropped by 7.3% from its highest level this year, and is about 50% above its lowest level this year. 

Bayer share price technical analysis

The daily chart shows that the Bayer stock price pulled back from the year-to-date high of €29.77 last month to the current €27.60. This chart shows that it has been forming a series of higher highs and higher lows, and is now at a lower point. 

Bayer stock price remains above the 50-day moving average, which has provided it with substantial support since May. The Relative Strength Index (RSI) has moved to the neutral point at 50.

Therefore, the stock will likely resume the uptrend as bulls target the year-to-date high of €29.77. A move above that level will point to more gains, potentially to €30.85, the highest point in September last year. This target price is about 12% above the current level. 

The bullish Bayer share price will be invalidated if it drops below the support at €26.8, which is the 50-day moving average. 

Bayer share price chart | Source: TradingView

Bayer earnings ahead

The most important catalyst for the Bayer stock price will be the upcoming financial results.

Its recent quarterly results will provide more color on its performance. The most recent results showed that its sales were flat to €13.73 billion as its volume and prices retreated. 

Most of the decline happened in the Latin American region, where sales dropped by 10.4% to €1.4 billion. Its EMEA sales also declined by 1.9%, but was partially offset by an increase in the North American and Asia Pacific regions.

READ MORE: Bayer share price is rising: does it have more upside?

The decline, as has happened in the past, was because of its crop science division. This division has deteriorated because of the weaker prices of top commodities like corn and soybeans.

Crop science’s revenue dropped by 4.1% to €7.9 billion. This decline was offset by a 4.4% increase in the pharmaceuticals division, whose revenue jumped by 4.4%. The division was boosted by the volume and price. 

Eylea’s sales rose to €815 million, while the Xarelto’s sales crashed by 31.6% to €633 million. Xarelto’s sales plunged because of the rising competition from genetics medicines. Some of its top growth drugs were Nubeqa, Aspirin, and Kerendia.

Analysts expect this week’s results to show that its revenue was €10.79 billion, with the strong euro having a 4.5% hit on its numbers. The average EBITDA is expected to be €1.8 billion, down from €2.1 billion last year, while its net income will be €67 million, a big improvement from the €34 million loss last year. 

Bayer will also update on the ongoing Roundup litigation. In May, WSJ said that it was seeking a settlement as it explored a Monsanto bankruptcy.

The post Here’s why the Bayer share price may rebound after earnings appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Tom Lee says US stocks will defy history in August
next post
Japan faces food security crisis amid record heat and stink bug infestation

Related Posts

How China’s DeepSeek’s rise cost the world’s richest...

January 28, 2025

Brazilian airline Gol secures $1.25 billion exit financing...

March 24, 2025

Boeing is laying off 10% of its workforce,...

October 12, 2024

AI16Z surpasses $2.7B market cap as AI agents...

January 2, 2025

S&P 500, Dow rise on strong US jobs...

October 5, 2024

Ferrari stock is severely overvalued: is it an...

September 29, 2024

Lloyds share price ripe for a breakout ahead...

July 8, 2025

Top FTSE 100 shares to watch: Persimmon, Antofagasta,...

August 8, 2025

Canoo stock forms rare pattern: could GOEV surge...

November 25, 2024

Who is Paik Jong-won and why is he...

October 25, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • FBI raid on John Bolton’s home in Washington linked to classified documents

      August 25, 2025
    • Argentine senate deals blow to Milei’s austerity agenda with university budget boost

      August 25, 2025
    • At Jackson Hole, Fed Chair Powell signals possible cuts while warning of uncertainty

      August 25, 2025
    • Jackson Hole Symposium: what Powell said about economic effects of Trump’s tariffs

      August 25, 2025
    • Trump threatens to fire Fed Governor Lisa Cook amid mortgage fraud allegations

      August 25, 2025

    Categories

    • Business (3,763)
    • Investing (2,783)
    • Latest News (2,048)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved